野村发表研究报告，维持国药控股(01099.HK) 的“买入”评级，目标价由28.46元降至25.09元。该行将集团2024及25年的销售预测各下调1.4%，并分别降盈测5.3%，以反映利润压力及信贷损失或减值。该行估计，国药上季收入将按年下降0.4%，而盈利则跌2.8%。(sl/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-26 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.